Table 3.
Frequency of drug use >2% in all patients, potential pharmacogenetic tests and number of performed tests (with percentages out of the patients treated with this drug). The marked medications (gray background) are medications related to rheumatic therapy; the other medications are used for the treatment of comorbidities.
| Drug | Number of Patients [n (% of Total)] |
Pharmacogenetic Testing | Performed Tests [n (%)] |
|---|---|---|---|
| Atorvastatin | 168 (6.7) | SLCO1B1 | 0 |
| AZA | 125 (5.0) | TPMT, NUDT15 | 93 (74.4), 0 |
| Tramadol | 99 (4.0) | CYP2D6 | 0 |
| Simvastatin | 83 (3.3) | SLCO1B1 | 0 |
| Estradiolvalerat | 54 (2.2) | F5 | 0 |
| Sertraline | 52 (2.1) | CYP2C19 | 0 |
SLCO1B1, solute carrier organic anion transporter family member 1B1; AZA, azathioprine; TPMT, thiopurine S-methyltransferase; NUDT15, nudix hydrolase 15; CYP2D6, cytochrome P450 family 2 subfamily D member 6; F5, coagulation factor V; CYP2C19, cytochrome P450 family 2 subfamily C member 19.